EXHIBIT 107
Calculation of Filing Fee Tables
Form S-3
(Form Type)
Inhibikase Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward Securities
| Security Type |
Security Class Title |
Fee Calculation or Carry Forward Rule |
Amount Registered(1) |
Proposed Maximum Offering Price Per Unit |
Maximum Aggregate Offering Price |
Fee Rate |
Amount of Registration Fee | |||||||||
| Newly Registered Securities | ||||||||||||||||
| Fees to Be Paid | Equity | Common Stock issuable upon exercise of Series A-1 Warrants |
457(c) | 40,139,474(2) | $3.225(3) | $129,449,803.65 | $0.00015310 | $19,818.77 | ||||||||
| Fees to Be Paid | Equity | Common Stock issuable upon exercise of Series B-1 Warrants |
457(c) | 73,813,529(2) | $3.225(3) | $238,048,631.025 | $0.00015310 | $36,445.25 | ||||||||
| Fees Previously Paid |
||||||||||||||||
| Carry Forward Securities | ||||||||||||||||
| Carry Forward Securities |
— | — | — | — | — | — | — | |||||||||
| Total Offering Amounts | $367,498,434.675 | $56,264.02 | ||||||||||||||
| Total Fees Previously Paid | — | $0 | ||||||||||||||
| Total Fee Offsets | — | $0 | ||||||||||||||
| Net Fee Due | $56,264.02 | |||||||||||||||
| (1) | Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement also registers an indeterminate number of shares of Inhibikase Therapeutics, Inc.’s common stock, $0.001 par value per share (the “Common Stock”), which may become issuable by reason of any stock dividend, stock split or other similar transaction effected without the receipt of consideration that results in an increase in the number of the outstanding shares of Common Stock. |
| (2) | The shares of Common Stock will be offered for resale by the selling stockholders pursuant to the prospectus contained in the registration statement to which this exhibit is attached. The registration statement registers the resale of an aggregate of 113,953,003 shares of Common Stock, which consists of (i) 40,139,474 shares of Common Stock issuable upon the exercise of outstanding Series A-1 Warrants, or in lieu thereof, pre-funded warrants to purchase the same number of shares of Common Stock and (ii) 73,813,529 shares of Common Stock issuable upon the exercise of outstanding Series B-1 Warrants, or in lieu thereof, pre-funded warrants to purchase the same number of shares of Common Stock. |
| (3) | Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) under the Securities Act, based on the average of the high and low prices of the Common Stock as reported on Nasdaq Capital Market on January 7, 2025 of $3.225 per share. |